Study: NCT04904588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-body irradiation
Description: Administered pre-transplant as part of conditioning regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-body irradiation
Description: Administered pre-transplant as part of conditioning regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-body irradiation
Description: Administered pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Hematopoietic Stem Cell Transplantation
Description: Bone marrow graft is infused from a mismatched unrelated donor on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Hematopoietic Stem Cell Transplantation
Description: Bone marrow graft is infused from a mismatched unrelated donor on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: Survey assessments will be administered to study participants pre- and post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: Survey assessments will be administered to study participants pre- and post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: Survey assessments will be administered to study participants pre- and post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: Survey assessments will be administered to study participants pre- and post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: Survey assessments will be administered to study participants pre- and post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: Survey assessments will be administered to study participants pre- and post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: Survey assessments will be administered to study participants pre- and post-transplant.